A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity.

Trial Profile

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms NP-MH
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
    • 28 Aug 2012 Primary endpoint 'Pain-intensity' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.
    • 28 Aug 2012 Primary endpoint 'Numerical-Rating-Scale' has been met, based on results presented at 14th World Congress on Pain. However, due to termination of the study for safety reasons, only 87 of the planned 385 patients were enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top